Topical imiquimod adverse event: Beyond the local skin reaction-A case report.

Florence Lagacé-Thomassin, Ariana Nateghi, Elio Kechichian, Mylène Veilleux

Abstract readCase Reports

In one paragraph

Article in SAGE open medical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Florence Lagacé-ThomassinDepartment of Dermatology, University of Sherbrooke, Sherbrooke, QC, Canada.

Ariana NateghiDepartment of Dermatology, University of Sherbrooke, Sherbrooke, QC, Canada.

Elio KechichianDepartment of Dermatology, University of Sherbrooke, Sherbrooke, QC, Canada.

Mylène VeilleuxDepartment of Dermatology, University of Sherbrooke, Sherbrooke, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imiquimod is a well-known topical treatment for its efficacy against various skin conditions. While generally well-tolerated, adverse reactions like local skin irritation are common. However, severe systemic effects such as Stevens-Johnson syndrome (SJS) are rare, but possible. We present the case of an 82-year-old male who developed SJS following topical Imiquimod therapy for basal cell carcinoma. Despite minimal systemic absorption, serious reactions can occur, warranting caution. Prompt recognition and discontinuation of treatment are crucial for managing such rare but severe adverse events. This case underscores the importance of informed consent and vigilant monitoring for adverse reactions associated with Imiquimod therapy.

Indexed as

adverse reactionsbasal cell carcinomaCase reportcutaneous skin reactionsimiquimodsevere cutaneous adverse reactionsStevens–Johnson syndrometoxic epidermal necrolysis

Identifiers

PMID39165296

DOI10.1177/2050313X241274916

PMCPMC11334118

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.